Home > Boards > Canadian > Medical - Healthcare > Canadian Theralase Technologies Inc. (TLT.V)
Followed By 5
Posts 295
Boards Moderated 0
Alias Born 11/01/2011

Thursday, April 03, 2014 7:16:01 AM

Re: None

Post# of 28
Theralase (TSXV: TLT) Advances Anti-Cancer Technology Platform

(via Thenewswire.ca)

Toronto, Ontario / TNW-ACCESSWIRE / April 3, 2014 / Theralase Technologies Inc. ("Theralase") (TSXV: TLT) (TLTFF: OTCBB) announced today that it has advanced its anti-cancer technology platform through an executed research agreement with Acadia University ("Acadia"). Under the terms of the agreement, Acadia will supply initial quantities of Theralase's lead Photo Dynamic Compounds (PDCs) and the Standard Operating Procedures (SOPs) of how to synthesize them.

The lead PDCs will be used by Theralase to commence toxicity analysis and manufacturing ramp up via Contract Manufacturing Organization (CMO); both mandatory prerequisites in the evolution towards an approved Investigational New Drug (IND) application from the FDA and Health Canada. With larger quantities of the PDCs in hand and an approved IND; Theralase would be in the position to commence a Phase 1/2a human clinical trial for the lead indication of bladder cancer, as early as 1Q2015.

The lead PDCs have advanced towards international patent protection under a filed Patent Cooperation Treaty (PCT) application. Once approved at this phase, the Company plans to provide wide spread patent coverage of the PDCs across numerous countries during the national phase.

Dr. Sherri McFarland, Professor of Chemistry at Acadia University, the originator of the PDCs under worldwide exclusive licence to Theralase stated, "I am truly excited to work with Theralase in the development of these PDCs and be associated with their lead scientists and clinical oncologists to develop the next generation of anti-cancer technology. From the raw research I have observed, this technology has the potential to not only destroy one type of cancer, but many. I am convinced that this technology has the opportunity to go mainstream as a primary treatment in the destruction of cancer, within the next few years."

Dr. David MacKinnon, Dean, Research and Graduate Studies at Acadia University stated, "We are pleased to have partnered with Theralase in the development of these PDCs for the destruction of cancer. It is rewarding to advance research originally developed in our chemistry labs from conception through to commercialization knowing that it may one day be a cure for cancer."

Dr. Arkady Mandel, Chief Scientific Officer of Theralase stated that, "Sherri's strong background as a medicinal chemist and specialist in photochemistry, coupled with my scientific and medical knowledge as to how laser light interacts at the molecular and cellular level, will bring a new platform of cutting-edge anti-cancer technologies to the forefront within the next few years."

Roger Dumoulin-White, President and CEO of Theralase stated that, "I am delighted that Acadia has partnered with Theralase in the commercialization of technology that may provide a new front line treatment for cancer in the not too distant future. With good partners, disruptive technologies are born, which can make marked impacts on devastating diseases such as cancer, in our lifetime. I am humbled to be part of the process."

About Theralase Technologies Inc.

Theralase Technologies Inc. designs, manufactures and markets patented, superpulsed laser technology used in eliminating pain and destroying cancer. Theralase technology is safe and effective in eliminating pain, reducing inflammation and accelerating tissue regeneration of numerous nerve, muscle and joint injuries. Theralase is actively developing patented technology that is able to target and destroy cancers, bacteria and viruses when light activated.

A.I.S. Resources Identifies Prospective Drill Targets at Reliance Reef and Provides Bright Gold Project Update AIS May 20, 2022 8:00 AM

Lomiko Announces Commencement of Exploration Drilling for its La Loutre Graphite Project LMR May 19, 2022 10:56 AM

PTOP Announces MOBICARD ™ 2.0 Development Contract has been executed PTOP May 19, 2022 10:00 AM

Edison Lithium Spin-Out of Cobalt Assets EDDYF May 19, 2022 8:00 AM

Goldshore Resources Announces Innovative Technology Application for Moss Lake Project Exploration and Closing of Non-Brokered Financing GSHRF May 19, 2022 8:00 AM

Demand Brands kicks off cultivation at Corralitos Farms DMAN May 18, 2022 2:00 PM

Emerging Markets Report: Details, Details SYTA May 18, 2022 11:48 AM

American Green, Inc. ™ (OTC:ERBB) Purchases 40,000sq.ft. Cannabis Grow Building for $3,750,000 ERBB May 18, 2022 9:25 AM

Green Battery Minerals Completes Resource Expansion Drilling at Zone 1 and Intersects Numerous Holes Ranging from 150 - 200 Feet of Graphite CZSVF May 18, 2022 9:19 AM

Grove Inc. Programmatic Ad Technology, Interactive Offers, Secures Milestone Patent GRVI May 18, 2022 9:11 AM

AgriFORCE Growing Systems Completes Acquisition of Food Production & Processing IP from Manna Nutritional Group (MNG) AGRI May 18, 2022 9:11 AM

HPIL Holding Secures a $CAD 32 Million Capital Commitment from GEM Global Yield LLC SCS ("GEM") HPIL May 18, 2022 9:00 AM

Branded Legacy, Inc. Increases Revenue By Expanding In New York and Florida Company Adds New Disposable Vapes BLEG May 18, 2022 8:30 AM

Demand Brands enters $8.5 million agreement with Truleaf, Inc. to enter the live rosin market DMAN May 18, 2022 8:00 AM

Emergency Response Technologies Inc, a Wholly Owned Subsidiary of ILUS International (Ilustrato Pictures International Inc), Confirms the Appointment of Law Firm Lucosky Brookman LLP to Assist with Upcoming Plans ILUS May 18, 2022 7:35 AM